181 related articles for article (PubMed ID: 16798938)
21. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
Pommier Y; Cushman M
Mol Cancer Ther; 2009 May; 8(5):1008-14. PubMed ID: 19383846
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of new dihydroindeno[1,2-c]isoquinoline and indenoisoquinolinium chloride topoisomerase I inhibitors having high in vivo anticancer activity in the hollow fiber animal model.
Jayaraman M; Fox BM; Hollingshead M; Kohlhagen G; Pommier Y; Cushman M
J Med Chem; 2002 Jan; 45(1):242-9. PubMed ID: 11754595
[TBL] [Abstract][Full Text] [Related]
23. Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.
Beck DE; Abdelmalak M; Lv W; Reddy PV; Tender GS; O'Neill E; Agama K; Marchand C; Pommier Y; Cushman M
J Med Chem; 2015 May; 58(9):3997-4015. PubMed ID: 25909279
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay.
Morrell A; Jayaraman M; Nagarajan M; Fox BM; Meckley MR; Ioanoviciu A; Pommier Y; Antony S; Hollingshead M; Cushman M
Bioorg Med Chem Lett; 2006 Aug; 16(16):4395-9. PubMed ID: 16750365
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis.
Ioanoviciu A; Antony S; Pommier Y; Staker BL; Stewart L; Cushman M
J Med Chem; 2005 Jul; 48(15):4803-14. PubMed ID: 16033260
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1).
Conda-Sheridan M; Reddy PV; Morrell A; Cobb BT; Marchand C; Agama K; Chergui A; Renaud A; Stephen AG; Bindu LK; Pommier Y; Cushman M
J Med Chem; 2013 Jan; 56(1):182-200. PubMed ID: 23259865
[TBL] [Abstract][Full Text] [Related]
27. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells.
Liu YP; Chen HL; Tzeng CC; Lu PJ; Lo CW; Lee YC; Tseng CH; Chen YL; Yang CN
Breast Cancer Res Treat; 2013 Apr; 138(2):383-93. PubMed ID: 23430225
[TBL] [Abstract][Full Text] [Related]
28. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
[TBL] [Abstract][Full Text] [Related]
29. 11H-Isoquino[4,3-c]cinnolin-12-ones; novel anticancer agents with potent topoisomerase I-targeting activity and cytotoxicity.
Ruchelman AL; Singh SK; Ray A; Wu X; Yang JM; Zhou N; Liu A; Liu LF; LaVoie EJ
Bioorg Med Chem; 2004 Feb; 12(4):795-806. PubMed ID: 14759740
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles.
Nagarajan M; Morrell A; Ioanoviciu A; Antony S; Kohlhagen G; Agama K; Hollingshead M; Pommier Y; Cushman M
J Med Chem; 2006 Oct; 49(21):6283-9. PubMed ID: 17034134
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons.
Beck DE; Lv W; Abdelmalak M; Plescia CB; Agama K; Marchand C; Pommier Y; Cushman M
Bioorg Med Chem; 2016 Apr; 24(7):1469-79. PubMed ID: 26906474
[TBL] [Abstract][Full Text] [Related]
32. Gold(III) complexes of pyridyl- and isoquinolylamido ligands: structural, spectroscopic, and biological studies of a new class of dual topoisomerase I and II inhibitors.
Wilson CR; Fagenson AM; Ruangpradit W; Muller MT; Munro OQ
Inorg Chem; 2013 Jul; 52(14):7889-906. PubMed ID: 23815163
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Part 2.
Tseng CH; Tzeng CC; Yang CL; Lu PJ; Chen HL; Li HY; Chuang YC; Yang CN; Chen YL
J Med Chem; 2010 Aug; 53(16):6164-79. PubMed ID: 20662543
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluations of novel indenoisoquinolines as topoisomerase I inhibitors.
Zhang X; Wang R; Zhao L; Lu N; Wang J; You Q; Li Z; Guo Q
Bioorg Med Chem Lett; 2012 Jan; 22(2):1276-81. PubMed ID: 22079759
[TBL] [Abstract][Full Text] [Related]
35. Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures.
Morrell A; Placzek MS; Steffen JD; Antony S; Agama K; Pommier Y; Cushman M
J Med Chem; 2007 May; 50(9):2040-8. PubMed ID: 17402722
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase I (Tdp1)-topoisomerase I (Top1) inhibitors.
Nguyen TX; Morrell A; Conda-Sheridan M; Marchand C; Agama K; Bermingham A; Bermingam A; Stephen AG; Chergui A; Naumova A; Fisher R; O'Keefe BR; Pommier Y; Cushman M
J Med Chem; 2012 May; 55(9):4457-78. PubMed ID: 22536944
[TBL] [Abstract][Full Text] [Related]
37. A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.
Liao ZY; Sordet O; Zhang HL; Kohlhagen G; Antony S; Gmeiner WH; Pommier Y
Cancer Res; 2005 Jun; 65(11):4844-51. PubMed ID: 15930305
[TBL] [Abstract][Full Text] [Related]
38. Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24).
Heffeter P; Jakupec MA; Körner W; Wild S; von Keyserlingk NG; Elbling L; Zorbas H; Korynevska A; Knasmüller S; Sutterlüty H; Micksche M; Keppler BK; Berger W
Biochem Pharmacol; 2006 Feb; 71(4):426-40. PubMed ID: 16343446
[TBL] [Abstract][Full Text] [Related]
39. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB
J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827
[TBL] [Abstract][Full Text] [Related]
40. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.
Marchand C; Antony S; Kohn KW; Cushman M; Ioanoviciu A; Staker BL; Burgin AB; Stewart L; Pommier Y
Mol Cancer Ther; 2006 Feb; 5(2):287-95. PubMed ID: 16505102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
